Murayama Y
Gan No Rinsho. 1984 Dec;30(15):1879-82.
We determined SHBG titer before and during hormone therapy for breast cancer. The increased SHBG titer was 78 +/- 29 pmol/ml of plasma in DES responsive breast cancer. However that of DES non-responsive breast cancer was 31 +/- 22 pmol/ml of plasma (p less than 0.01). SHBG titer was increased during the administration of tamoxifen and was decreased during that of fluoxymesterone and after surgical hormone therapy. These results indicate that the mechanism of hormone therapy was due to a decreased free estradiol, which was caused by increased SHBG titer and resection of the ovarium or adrenal gland.
我们测定了乳腺癌激素治疗前后的性激素结合球蛋白(SHBG)水平。在己烯雌酚(DES)敏感的乳腺癌中,SHBG水平升高为血浆78±29 pmol/ml。然而,DES不敏感的乳腺癌患者血浆SHBG水平为31±22 pmol/ml(p<0.01)。在服用他莫昔芬期间SHBG水平升高,而在服用氟甲睾酮期间及手术激素治疗后SHBG水平降低。这些结果表明,激素治疗的机制是由于游离雌二醇减少,这是由SHBG水平升高以及卵巢或肾上腺切除所致。